Zion Johnson has yet to live up to his first-round billing but the Chargers are hoping a position change can elevate his game ...

The senior won Miss Maine Field Hockey and led the Cheverus field hockey and ice hockey teams to their third state championships — each — during her four years.

Kostecki prevailed in the first race of the weekend as a struggling Feeney maintained his championship lead ...

Medtronic is approaching five decades of dividend growth. AbbVie rose to the challenge when its Humira patent expired, cementing its sterling reputation. Johnson & Johnson is a model of consistency ...

The Angels were hopeful that right-hander Jack Kochanowicz would build on his solid rookie season, but instead he’s enduring ...

When his colleagues think of the kind of judge that the Honorable Theodore O. Johnson was, they all had this to say in common ...

Peyton Johnson joined WCTV's Taylor Viles for a three-hole scramble match interview. They talked about the high school junior ...

The party is seeking a pathway back to power in Washington but is grappling for a message that will resonate with the working ...

In the assessment of 12-month price targets, analysts unveil insights for Johnson & Johnson, presenting an average target of $168.25, a high estimate of $181.00, and a low estimate of $153.00.

Johnson & Johnson's 2025 outlook sees slight EPS and revenue upgrades, while headwinds from biosimilars and tariffs are ...

JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 ...

J&J(JNJ) wins U.S. appeals court case protecting its Invega Sustenna patent from generic rivals Viatris (VTRS) & Teva (TEVA).